Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.

Mensah AA, Cascione L, Gaudio E, Tarantelli C, Bomben R, Bernasconi E, Zito D, Lampis A, Hahne JC, Rinaldi A, Stathis A, Zucca E, Kwee I, Gattei V, Valeri N, Riveiro ME, Bertoni F.

Haematologica. 2018 Aug 3. pii: haematol.2018.191684. doi: 10.3324/haematol.2018.191684. [Epub ahead of print]

2.

Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization.

Sbattella M, Zanichelli A, Ghia P, Gattei V, Suffritti C, Teatini T, Cicardi M, Castelli R.

Med Oncol. 2018 Aug 2;35(9):118. doi: 10.1007/s12032-018-1183-7.

PMID:
30073422
3.

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Raponi S, Del Giudice I, Ilari C, Cafforio L, Messina M, Cappelli LV, Bonina S, Piciocchi A, Marinelli M, Peragine N, Mariglia P, Mauro FR, Rigolin GM, Rossi F, Bomben R, Dal Bo M, Del Poeta G, Diop F, Favini C, Rossi D, Gaidano G, Cuneo A, Gattei V, Guarini A, Foá R.

Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15405. [Epub ahead of print] No abstract available.

PMID:
29785734
4.

Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases.

Mazzaro C, Maso LD, Mauro E, Gattei V, Ghersetti M, Bulian P, Moratelli G, Grassi G, Zorat F, Pozzato G.

Diseases. 2018 May 3;6(2). pii: E35. doi: 10.3390/diseases6020035.

5.

Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2-202 has prognostic value in Chronic Lymphocytic Leukaemia.

Bomben R, Roisman A, D'Agaro T, Castellano G, Baumann T, Delgado J, López-Guillermo A, Zucchetto A, Dal-Bo M, Bravin V, Slavutsky I, Vlasova A, Guigó R, Martin-Subero JI, Chapaprieta V, Beekman R, Martin-García D, Beà S, Salaverria I, Aymerich M, Campo E, Gattei V, Hernández L.

Br J Haematol. 2018 Apr 24. doi: 10.1111/bjh.15237. [Epub ahead of print] No abstract available.

PMID:
29687884
6.

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.

Bomben R, Ferrero S, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Liu D, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M, Gattei V.

Haematologica. 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22.

7.

Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study.

Mazzaro C, Dal Maso L, Quartuccio L, Ghersetti M, Lenzi M, Mauro E, Bond M, Casarin P, Gattei V, Crosato IM, De Vita S, Pozzato G.

Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):107-114. Epub 2018 Feb 13.

8.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

9.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.

Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24.

PMID:
29066507
10.

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A.

Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22.

PMID:
28935990
11.

Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing.

Zamò A, Pischimarov J, Schlesner M, Rosenstiel P, Bomben R, Horn H, Grieb T, Nedeva T, López C, Haake A, Richter J, Trümper L, Lawerenz C, Klapper W, Möller P, Hummel M, Lenze D, Szczepanowski M, Flossbach L, Schreder M, Gattei V, Ott G, Siebert R, Rosenwald A, Leich E.

Leukemia. 2018 Mar;32(3):685-693. doi: 10.1038/leu.2017.270. Epub 2017 Aug 21.

PMID:
28824170
12.

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.

Sonego M, Pellizzari I, Dall'Acqua A, Pivetta E, Lorenzon I, Benevol S, Bomben R, Spessotto P, Sorio R, Gattei V, Belletti B, Schiappacassi M, Baldassarre G.

Sci Rep. 2017 Aug 2;7(1):7104. doi: 10.1038/s41598-017-07005-1.

13.

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.

Bulian P, Bomben R, Bo MD, Zucchetto A, Rossi FM, Degan M, Pozzo F, Bittolo T, Bravin V, D'Agaro T, Cerri M, Chiarenza A, Chaffee KG, Condoluci A, D'Arena G, Spina M, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Poeta GD, Gaidano G, Shanafelt TD, Gattei V.

Haematologica. 2017 Nov;102(11):e443-e446. doi: 10.3324/haematol.2017.170340. Epub 2017 Jul 27. No abstract available.

14.

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R.

Br J Haematol. 2018 Aug;182(4):597-602. doi: 10.1111/bjh.14843. Epub 2017 Jul 12. No abstract available.

PMID:
28699643
15.

Hepatitis C Virus-Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment.

Pozzato G, Mazzaro C, Gattei V.

Clin Liver Dis. 2017 Aug;21(3):499-515. doi: 10.1016/j.cld.2017.03.006. Epub 2017 May 18. Review.

PMID:
28689589
16.

Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia.

Bittolo T, Pozzo F, Bomben R, D'Agaro T, Bravin V, Bulian P, Rossi FM, Zucchetto A, Degan M, Macor P, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Haematologica. 2017 Aug;102(8):e305-e309. doi: 10.3324/haematol.2016.162594. Epub 2017 May 26. No abstract available.

17.

High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia.

Vendramini E, Giordan M, Giarin E, Michielotto B, Fazio G, Cazzaniga G, Biondi A, Silvestri D, Valsecchi MG, Muckenthaler MU, Kulozik AE, Gattei V, Izraeli S, Basso G, Te Kronnie G.

Oncotarget. 2017 Jun 27;8(26):42398-42413. doi: 10.18632/oncotarget.16392.

18.

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.

Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21.

PMID:
28321119
19.

Low-dose radiotherapy in diffuse large B-cell lymphoma.

Furlan C, Canzonieri V, Spina M, Michieli M, Ermacora A, Maestro R, Piccinin S, Bomben R, Dal Bo M, Trovo M, Gattei V, Tirelli U, Franchin G, Bulian P.

Hematol Oncol. 2017 Dec;35(4):472-479. doi: 10.1002/hon.2368. Epub 2016 Oct 25.

PMID:
27781290
20.

Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia.

Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben R, Poeta GD, Gaidano G, Rossi FM, Bulian P, Zucchetto A, Gattei V.

Curr Cancer Drug Targets. 2016;16(8):659-668. Review.

PMID:
27514846
21.

A case of SRSF2 mutation in chronic lymphocytic leukemia.

Garza E, Del Poeta G, Martínez-Losada C, Catalano G, Borgia L, Piredda ML, Fabiani E, Gattei V, Lo-Coco F, Noguera NI.

Leuk Res Rep. 2016 Jun 23;6:11-4. doi: 10.1016/j.lrr.2016.03.001. eCollection 2016.

22.

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.

Zucchetto A, Tissino E, Hartmann TN, Chigaev A, Del Poeta G, Colombatti A, Gattei V.

Clin Cancer Res. 2016 Jul 1;22(13):3410-1. doi: 10.1158/1078-0432.CCR-16-0050. No abstract available.

23.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S.

Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Review.

PMID:
27252989
24.

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Dal Bo M, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F, Tissino E, Benedetti D, Bittolo T, Nanni P, Cattarossi I, Zaina E, Chivilò H, Degan M, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Principe MI, Del Poeta G, Rossi D, Gaidano G, Gattei V.

Leukemia. 2016 Oct;30(10):2011-2018. doi: 10.1038/leu.2016.88. Epub 2016 Apr 25.

PMID:
27109509
25.

Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC.

Mazzaro C, Dal Maso L, Urraro T, Mauro E, Castelnovo L, Casarin P, Monti G, Gattei V, Zignego AL, Pozzato G.

Dig Liver Dis. 2016 Jul;48(7):780-4. doi: 10.1016/j.dld.2016.03.018. Epub 2016 Apr 2.

PMID:
27106525
26.

A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.

Yigit B, Halibozek PJ, Chen SS, O'Keeffe MS, Arnason J, Avigan D, Gattei V, Bhan A, Cen O, Longnecker R, Chiorazzi N, Wang N, Engel P, Terhorst C.

Oncotarget. 2016 May 3;7(18):26346-60. doi: 10.18632/oncotarget.8378.

27.

Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.

Rasi S, Khiabanian H, Ciardullo C, Terzi-di-Bergamo L, Monti S, Spina V, Bruscaggin A, Cerri M, Deambrogi C, Martuscelli L, Biasi A, Spaccarotella E, De Paoli L, Gattei V, Foà R, Rabadan R, Gaidano G, Rossi D.

Haematologica. 2016 Apr;101(4):e135-8. doi: 10.3324/haematol.2015.136051. Epub 2016 Jan 27. No abstract available.

28.

Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.

Pozzato G, Mazzaro C, Dal Maso L, Mauro E, Zorat F, Moratelli G, Bulian P, Serraino D, Gattei V.

World J Hepatol. 2016 Jan 18;8(2):107-16. doi: 10.4254/wjh.v8.i2.107. Review.

29.

Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.

Ganghammer S, Gutjahr J, Hutterer E, Krenn PW, Pucher S, Zelle-Rieser C, Jöhrer K, Wijtmans M, Leurs R, Smit MJ, Gattei V, Greil R, Hartmann TN.

Haematologica. 2016 Mar;101(3):e99-102. doi: 10.3324/haematol.2015.133470. Epub 2015 Nov 20. No abstract available.

30.

Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.

Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Rossi FM, Zucchetto A, Rossi D, Bomben R, Maurillo L, Cefalo M, De Santis G, Venditti A, Gaidano G, Amadori S, de Fabritiis P, Gattei V, Del Poeta G.

Haematologica. 2016 Jan;101(1):77-85. doi: 10.3324/haematol.2015.131854. Epub 2015 Nov 12.

31.

CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology.

Engel P, Boumsell L, Balderas R, Bensussan A, Gattei V, Horejsi V, Jin BQ, Malavasi F, Mortari F, Schwartz-Albiez R, Stockinger H, van Zelm MC, Zola H, Clark G.

J Immunol. 2015 Nov 15;195(10):4555-63. doi: 10.4049/jimmunol.1502033.

32.

p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability.

Fabris L, Berton S, Pellizzari I, Segatto I, D'Andrea S, Armenia J, Bomben R, Schiappacassi M, Gattei V, Philips MR, Vecchione A, Belletti B, Baldassarre G.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13916-21. doi: 10.1073/pnas.1508514112. Epub 2015 Oct 28.

33.

The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential.

Dal Bo M, Bomben R, Hernández L, Gattei V.

Oncotarget. 2015 Aug 14;6(23):19381-92. Review.

34.

Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.

Muccio VE, Saraci E, Gilestro M, Gattei V, Zucchetto A, Astolfi M, Ruggeri M, Marzanati E, Passera R, Palumbo A, Boccadoro M, Omedè P.

Cytometry B Clin Cytom. 2016 Jan;90(1):81-90. doi: 10.1002/cyto.b.21279. Epub 2015 Sep 23.

35.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

36.

Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?

Benedetti D, Tissino E, Caldana C, Dal Bo M, Bomben R, Marconi D, Ganghammer S, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Del Poeta G, VanMeter A, Zucchetto A, Espina V, Liotta L, Gattei V.

Leukemia. 2016 Feb;30(2):513-7. doi: 10.1038/leu.2015.149. Epub 2015 Jun 19. No abstract available.

PMID:
26183532
37.

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E, Gizdic B, Rossi FM, Bomben R, Zucchetto A, Benedetti D, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Deaglio S, Gattei V, Dal Bo M.

Leukemia. 2016 Jan;30(1):182-9. doi: 10.1038/leu.2015.182. Epub 2015 Jul 13.

PMID:
26165233
38.

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.

Dal Bo M, D'Agaro T, Gobessi S, Zucchetto A, Dereani S, Rossi D, Zaja F, Pozzato G, Di Raimondo F, Gaidano G, Laurenti L, Del Poeta G, Efremov DG, Gattei V, Bomben R.

Oncotarget. 2015 Aug 7;6(22):19102-17.

39.

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.

Ganghammer S, Hutterer E, Hinterseer E, Brachtl G, Asslaber D, Krenn PW, Girbl T, Berghammer P, Geisberger R, Egle A, Zucchetto A, Kruschinski A, Gattei V, Chigaev A, Greil R, Hartmann TN.

Oncotarget. 2015 May 20;6(14):12048-60.

40.

Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis.

Mazzaro C, Panarello G, Mauro E, Gattei V, Pozzato G.

Dig Liver Dis. 2015 Jul;47(7):613-6. doi: 10.1016/j.dld.2015.03.020. Epub 2015 Mar 31.

PMID:
25890508
42.

Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.

Famà R, Bomben R, Rasi S, Dal Bo M, Ciardullo C, Monti S, Rossi F, D'Agaro T, Zucchetto A, Gattei V, Gaidano G, Rossi D.

Blood. 2014 Dec 11;124(25):3831-3. doi: 10.1182/blood-2014-08-592725. No abstract available.

43.

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia.

Wang J, Khiabanian H, Rossi D, Fabbri G, Gattei V, Forconi F, Laurenti L, Marasca R, Del Poeta G, Foà R, Pasqualucci L, Gaidano G, Rabadan R.

Elife. 2014 Dec 11;3. doi: 10.7554/eLife.02869.

44.

Genetic characterization of p27(kip1) and stathmin in controlling cell proliferation in vivo.

Berton S, Pellizzari I, Fabris L, D'Andrea S, Segatto I, Canzonieri V, Marconi D, Schiappacassi M, Benevol S, Gattei V, Colombatti A, Belletti B, Baldassarre G.

Cell Cycle. 2014;13(19):3100-11. doi: 10.4161/15384101.2014.949512.

45.

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia.

Dereani S, Macor P, D'Agaro T, Mezzaroba N, Dal-Bo M, Capolla S, Zucchetto A, Tissino E, Del Poeta G, Zorzet S, Gattei V, Bomben R.

J Hematol Oncol. 2014 Oct 23;7:79. doi: 10.1186/s13045-014-0079-z.

46.

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms.

Hutterer E, Asslaber D, Caldana C, Krenn PW, Zucchetto A, Gattei V, Greil R, Hartmann TN.

Br J Haematol. 2015 Apr;169(2):286-9. doi: 10.1111/bjh.13188. Epub 2014 Oct 17. No abstract available.

47.

The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.

Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D.

Leukemia. 2015 Feb;29(2):503-7. doi: 10.1038/leu.2014.294. Epub 2014 Oct 6. No abstract available.

PMID:
25283840
48.

Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.

Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben R, Del Poeta G, Gaidano G, Rossi FM, Zucchetto A, Gattei V.

Semin Hematol. 2014 Jul;51(3):168-76. doi: 10.1053/j.seminhematol.2014.05.002. Epub 2014 May 15. Review.

PMID:
25048781
49.

The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A, Zucchetto A, Tissino E, Vitale C, Coscia M, Usai C, Pepper C, Gattei V, Bruzzone S, Deaglio S.

Leukemia. 2015 Feb;29(2):356-68. doi: 10.1038/leu.2014.207. Epub 2014 Jul 3.

PMID:
24990614
50.

NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.

Bo MD, Del Principe MI, Pozzo F, Ragusa D, Bulian P, Rossi D, Capelli G, Rossi FM, Niscola P, Buccisano F, Bomben R, Zucchetto A, Maurillo L, de Fabritiis P, Amadori S, Gaidano G, Gattei V, Del Poeta G.

Ann Hematol. 2014 Oct;93(10):1765-74. doi: 10.1007/s00277-014-2117-x. Epub 2014 Jun 13.

PMID:
24923451

Supplemental Content

Loading ...
Support Center